Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim: This randomized, double‐blind study evaluated the efficacy of switching from atorvastatin (ATV) 10 mg to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg, EZE/SIMVA 10/40 mg or doubling the dose of ATV from 10 to 20 mg in patients with type 2 diabetes (T2D). Methods: Eligible patients had haemoglobin A 1C ≤10%, were aged ≥18 years and were on ATV 10 mg for ≥6 weeks before study entry. After a 4‐week open‐label ATV 10 mg run‐in, patients were randomized to EZE/SIMVA 10/20 mg (n = 220), EZE/SIMVA 10/40 mg (n = 222) or ATV 20 g (n = 219) daily for 6 weeks. Results: Greater (p ≤ 0.001) reductions in low‐density lipoprotein cholesterol (LDL‐C) (the primary end‐point) were achieved by switching to EZE/SIMVA 10/20 mg (26.2%) or 10/40 mg (30.1%) than by doubling the dose of ATV to 20 mg (8.5%). EZE/SIMVA 10/20 mg and 10/40 mg produced greater (p ≤ 0.001) reductions in total cholesterol, non‐high‐density lipoprotein cholesterol (HDL‐C) and apolipoprotein B relative to ATV 20 mg. A reduction (p ≤ 0.050) in C‐reactive protein was observed with EZE/SIMVA 10/40 mg vs. ATV 20 mg. Similar reductions in triglycerides were observed across the three groups, and none of the treatments produced a significant change in HDL‐C. A greater (p ≤ 0.001) proportion of patients achieved LDL‐C <2.5 mmol/l with EZE/SIMVA 10/20 mg (90.5%) and 10/40 mg (87.0%) than with ATV 20 mg (70.4%). Both EZE/SIMVA doses were generally well tolerated, with an overall safety profile similar to ATV 20 mg. Conclusions: EZE/SIMVA 10/20 and 10/40 mg provided greater lipid‐altering efficacy than doubling the dose of ATV from 10 to 20 mg and were well tolerated in patients with T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Ballantyne, C. M., Blazing, M. A., King, T. R., Brady, W. E., & Palmisano, J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.060 · Cited by 202
Frost, P. H., & Havel, R. J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00034-4 · Cited by 193
Kosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S. E., Patrick, J. E., Cutler, D. L., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01633.x · Cited by 117
Cited by
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,042
Morrone, D., Weintraub, W. S., Toth, P. P., Hanson, M. E., Lowe, R. S., Lin, J., Shah, A. K., & Tershakovec, A. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.016 · Cited by 263
Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84
Self-citationSharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
“…Ballantyne et al, 2004 (45) Gagné et al, 2002 (55) Geiss et al, 2005 (35)† McKenney et al, 2007 (80) Goldberg et al, 2006 (86) Catapano et al, 2006 (88) Constance et al, 2007 (95) Reckless et al, 2008 (106) Roeters van Lennep et al, 2008 (108) Türk et al, 2008 (117)* Athyros et al, 2002 (56)…”
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Metadata
- Authors
- Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson‐Levonas, A. O., Massaad, R., & Allen, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2007-04-19
- Volume
- 9
- Issue
- 4
- Pages
- 575-584
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2144790234
- Cited by
- 40
- References
- 6
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00725.x
- The paper
- Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson‐Levonas, A. O., Massaad, R., & Allen, C. (2007). Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00725.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.